#BEGIN_DRUGCARD DB00355

# AHFS_Codes:
Not Available

# ATC_Codes:
J01DF01

# Absorption:
Less than 1% absorbed from the gastrointestinal tract following oral administration. Completely absorbed following intramuscular administration.

# Biotransformation:
Approximately 6 to 16% metabolized to inactive metabolites by hydrolysis of the beta-lactam bond, resulting in an open-ring compound.

# Brand_Mixtures:
Not Available

# Brand_Names:
Azactam
Corus 1020
Dynabiotic
Monobactam
Primbactam

# CAS_Registry_Number:
78110-38-0

# ChEBI_ID:
161680

# Chemical_Formula:
C13H17N5O8S2

# Chemical_IUPAC_Name:
(2S,3S)-3-[(2Z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-methyl-4-oxoazetidine-1-sulfonate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms. [PubChem]

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents

# Drug_Interactions:
Demeclocycline	Possible antagonism of action
Doxycycline	Possible antagonism of action
Ethinyl Estradiol	This anti-infectious agent could decrease the effect of the oral contraceptive
Minocycline	Possible antagonism of action
Tetracycline	Possible antagonism of action

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Aztreonam

# HET_ID:
AZR

# Half_Life:
The serum half-life of aztreonam averaged 1.7 hours (1.5 to 2.0) in subjects with normal renal function, independent of the dose. In elderly patients and in patients with impaired renal function, the mean serum half-life of aztreonam increased (4.7 to 6 hours and 2.1 hours, respectively).

# InChI_Identifier:
InChI=1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1

# InChI_Key:
InChIKey=WZPBZJONDBGPKJ-VEHQQRBSSA-N

# Indication:
For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.

# KEGG_Compound_ID:
C06840

# KEGG_Drug_ID:
D00240

# LIMS_Drug_ID:
355

# Mechanism_Of_Action:
The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that aztreonam interferes with an autolysin inhibitor.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
435.433

# Molecular_Weight_Mono:
435.051853925

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1FR6

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448523

# Pharmacology:
Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from <i>Chromobacterium violaceum</i>. Aztreonam exhibits potent and specific activity in vitro against a wide spectrum of gram-negative aerobic pathogens including <i>Pseudomonas aeruginosa</i>. It has no useful activity against gram-positive bacteria or anaerobes, but has very broad spectrum against gram-negative aerobes, including <i>Pseudomonas aeruginosa</i>. This has given it the nickname "the magic bullet for aerobic gram-negative bacteria". Aztreonam, unlike the majority of beta-lactam antibiotics, does not induce beta-lactamase activity and its molecular structure confers a high degree of resistance to hydrolysis by beta-lactamases (such as penicillinases and cephalosporinases) produced by most gram-negative and gram-positive pathogens; it is, therefore, usually active against gram-negative aerobic microorganisms that are resistant to antibiotics hydrolyzed by beta-lactamases. It is active against many strains that are multiply-resistant to other antibiotics, such as certain cephalosporins, penicillin, and aminoglycosides. Aztreonam maintains its antimicrobial activity over a pH range of 6 to 8 in vitro, as well as in the presence of human serum and under anaerobic conditions.

# Predicted_LogP_Hydrophobicity:
0.04

# Predicted_LogS:
-4.1

# Predicted_Water_Solubility:
4.29e-02 g/l

# Primary_Accession_No:
DB00355

# Protein_Binding:
Serum protein binding averaged 56% and is independent of dose. Impaired renal function, 36 to 43%.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic4/azactaminj.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00815
EXPT00605

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
AZT

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:16 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Aztreonam

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2244291	Rittenbury MS: How and why aztreonam works. Surg Gynecol Obstet. 1990;171 Suppl:19-23.
7487468	Mock CN, Jurkovich GJ, Dries DJ, Maier RV: Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg. 1995 Nov;130(11):1234-40; discussion 1240-1.
9145861	Fung-Tomc J, Bush K, Minassian B, Kolek B, Flamm R, Gradelski E, Bonner D: Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother. 1997 May;41(5):1010-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D38161

# Drug_Target_1_GenBank_ID_Protein:
790944

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
pbpC

# Drug_Target_1_Gene_Sequence:
>2007 bp
ATGTTAAAAAAGTGTATTCTACTAGTATTTCTATGCGTCGGATTGATTGGGTTAATCGGA
TGCTCCAAAACAGATTCACCAGAGGATCGCATGGAAGCATTCGTGAAACAGTGGAACGAT
CAGCAATTCGATGACATGTATCAAAGCCTGACTAAAGATGTCAAAAAAGAAATCTCCAAA
AAAGATTTCGTCAACAGGTATAAAGCCATCTATGAGCAGGCCGGCGTAAAAAATTTGAAA
GTCACTGCGGGAGAAGTAGATAAGGACGATCAAGACAACAAGACGATGAAACATATCCCG
TATAAAGTCAGCATGAACACAAATGCCGGCAAAGTCAGCTTCAAGAATACTGCTGTGCTG
AAATTAGAAAAAACAGATGACGAGGAGTCATGGAATATAGATTGGGACCCATCGTTTATT
TTCAAGCAGCTGGCTGACGACAAAACCGTGCAAATTATGAGCATTGAACCGAAACGAGGC
CAAATTTACGATAAAAATGGAAAAGGCTTAGCCGTCAATACAGATGTTCCGGAAATTGGA
ATTGTTCCCGGAGAGCTTGGCGATAAAAAAGAGAAAGTCATAAAAGAACTCGCCAAAAAA
CTTGATTTGACTGAAGACGACATCAAGAAAAAGCTGGATCAAGGCTGGGTAAAAGACGAT
TCGTTTGTGCCGCTCAAAAAGGTCAAGCCTGACCAGGAGAAATTAGTTTCTGAAGCGACG
TCATTACAAGGCGTAACAAGAACGAATGTCAGCTCCCGCTACTATCCGTATGGCGAAAAG
ACAGCCCATTTGACAGGCTATGTCCGCGCCATTACAGCGGAAGAACTGAAGAAAAAGAAA
GAAGGAACGTACAGCGATACGTCTAACATCGGTATCGCCGGACTTGAAAATGTGTATGAA
GACAAGCTAAGAGGCACAACTGGCTGGAAAATCTACGTGCCGCAAACCGGGGAAGTCATC
GCTGAAAAGAAAGCAAAGGACGGCGAGGATCTTCACCTCACAATTGATATCAAAACGCAA
ATGAAGCTGTATGATGAACTGAAGGATGACAGCGGGGCGGCAGTCGCGCTGCAGCCGAAG
ACAGGCGAAACACTCGCCCTTGTCAGCGCGCCTTCCTACGATCCAAACGGATTTATTTTC
GGCTGGAGCGATAAGGAATGGAAAAAGCTAAACAAAGATAAAAACAATCCGTTTTCAGCG
AAATTCAATAAGACATACGCGCCAGGTTCTACCATTAAACCGATTGCGGCTGCTATTGGA
ATCAAAAACGGCACCCTTAAAGCCGATGAGAAGAAAACAATCAAAGGCAAGGAGTGGCAA
AAAGATTCAAGCTGGGGCGGCTATTCAGTGACACGTGTGTCTGAGAGACTTCAACAAGTC
GATTTGGAAAACGCCCTTATTACGTCAGACAATATTTATTTTGCCCAGAATGCGCTTGAT
ATGGGAGCGGACACCTTTACAAAAGGCTTGAAGACATTCGGTTTTTCAGAGGACGTTCCG
TACGAATTCCCGATCCAGAAATCGTCTATTGCAAATGACAAGCTTGATTCAGACATTTTG
CTTGCGGATACAGGCTACGGACAAGGGCAAATGCAAATGTCTCCGCTTCACTTGGCAACT
GCTTACACGCCATTTGTTGACAATGGAGACCTTGTCAAACCGACGCTGATCAAAAAAGAT
TCACAAACAGCTGATGTTTGGCACAAGCAAGTGGTCACGAAGGAAGGAGCGGCAGACATT
ACAAAAGGTCTGAAAGGCGTTGTGGAAGATGAGCGCGGATCAGCGTATCAGCCTGTCGTG
AAAGGAATCACAGTGGCTGGAAAAACAGGAACAGCCGAGCTGAAAACATCAAAAGATGAT
AAAGACGGCACGGAAAATGGCTGGTTTGTCGGCTACGATTACGAAAACAAAGACCTGCTT
GTCGCCATGATGATCCAAAATGTGCAGGACCGCGGCGGCAGCCACTATGTCGTTGAGAAA
GCGAAAAAGCAATTTCAATCGAATTAA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
3145906	Smith H, de Jong A, Bron S, Venema G: Characterization of signal-sequence-coding regions selected from the Bacillus subtilis chromosome. Gene. 1988 Oct 30;70(2):351-61.
8969502	Yamane K, Kumano M, Kurita K: The 25 degrees-36 degrees region of the Bacillus subtilis chromosome: determination of the sequence of a 146 kb segment and identification of 113 genes. Microbiology. 1996 Nov;142 ( Pt 11):3047-56.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
867

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
74407

# Drug_Target_1_Name:
Penicillin-binding protein 3

# Drug_Target_1_Number_of_Residues:
668

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer
PF05223	MecA_N

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 3
MLKKCILLVFLCVGLIGLIGCSKTDSPEDRMEAFVKQWNDQQFDDMYQSLTKDVKKEISK
KDFVNRYKAIYEQAGVKNLKVTAGEVDKDDQDNKTMKHIPYKVSMNTNAGKVSFKNTAVL
KLEKTDDEESWNIDWDPSFIFKQLADDKTVQIMSIEPKRGQIYDKNGKGLAVNTDVPEIG
IVPGELGDKKEKVIKELAKKLDLTEDDIKKKLDQGWVKDDSFVPLKKVKPDQEKLVSEAT
SLQGVTRTNVSSRYYPYGEKTAHLTGYVRAITAEELKKKKEGTYSDTSNIGIAGLENVYE
DKLRGTTGWKIYVPQTGEVIAEKKAKDGEDLHLTIDIKTQMKLYDELKDDSGAAVALQPK
TGETLALVSAPSYDPNGFIFGWSDKEWKKLNKDKNNPFSAKFNKTYAPGSTIKPIAAAIG
IKNGTLKADEKKTIKGKEWQKDSSWGGYSVTRVSERLQQVDLENALITSDNIYFAQNALD
MGADTFTKGLKTFGFSEDVPYEFPIQKSSIANDKLDSDILLADTGYGQGQMQMSPLHLAT
AYTPFVDNGDLVKPTLIKKDSQTADVWHKQVVTKEGAADITKGLKGVVEDERGSAYQPVV
KGITVAGKTGTAELKTSKDDKDGTENGWFVGYDYENKDLLVAMMIQNVQDRGGSHYVVEK
AKKQFQSN

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P42971

# Drug_Target_1_SwissProt_Name:
PBPC_BACSU

# Drug_Target_1_Synonyms:
PBP 3
PSPB20

# Drug_Target_1_Theoretical_pI:
6.56

# Drug_Target_1_Transmembrane_Regions:
7-23

# Drug_Target_2_Cellular_Location:
Periplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16048994	Poirel L, Brinas L, Fortineau N, Nordmann P: Integron-encoded GES-type extended-spectrum beta-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005 Aug;49(8):3593-7.
16401074	Diaz N, Suarez D, Sordo TL: Molecular dynamics simulations of class C beta-lactamase from Citrobacter freundii: insights into the base catalyst for acylation. Biochemistry. 2006 Jan 17;45(2):439-51.
16792938	Mirelis B, Rivera A, Miro E, Mesa RJ, Navarro F, Coll P: A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli. Enferm Infecc Microbiol Clin. 2006 Jun-Jul;24(6):370-2.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X03866

# Drug_Target_2_GenBank_ID_Protein:
40452

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ampC

# Drug_Target_2_Gene_Sequence:
>1146 bp
ATGATGAAAAAATCGATATGCTGCGCGCTGCTGCTGACAGCCTCTTTCTCCACGTTTGCT
GCCGCAAAAACAGAACAACAAATTGCCGATATCGTTAACCGCACCATCACACCACTGATG
CAGGAGCAGGCTATTCCGGGTATGGCCGTGGCGATTATCTACGAGGGGAAACCTTATTAC
TTTACCTGGGGTAAAGCCGATATCGCCAATAACCACCCAGTCACGCAGCAAACGCTGTTT
GAGCTAGGGTCGGTCAGTAAGACGTTTAACGGCGTGTTGGGCGGCGACCGTATCGCCCGC
GGCGAAATTAAGCTCAGCGATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAG
TGGCGGGGTATCAGCCTGCTGCACTTAGCCACCTATACAGCGGGTGGCCTGCCGCTGCAG
ATCCCCGGTGACGTTACGGATAAAGCCGAATTACTGCGCTTTTATCAAAACTGGCAACCA
CAATGGACTCCGGGCGCTAAGCGTCTTTACGCTAACTCCAGCATTGGTCTGTTTGGTGCG
CTGGCGGTGAAATCTTCAGGTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAA
CCATTAAAACTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAACTATGCC
TGGGGCTATCTCGAAGGGAAGCCTGTGCACGTTTCTCCGGGACAACTTGACGCCGAAGCC
TATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCC
AGCCACGTTCAGGAGAAAACGCTCCAGCAGGGCATTGAGCTTGCGCAGTCTCGCTACTGG
CGTATTGGTGATATGTACCAGGGATTAGGCTGGGAGATGCTGAACTGGCCGCTGAAAGCT
GATTCGATCATCAACGGCAGCGACAGCAAAGTGGCATTGGCAGCGCTTCCCGCCGTTGAG
GTAAACCCGCCAGCACCTGCCGTGAAAGCCTCATGGGTGCATAAAACAGGATCCACAGGC
GGATTTGGCAGCTACGTTGCTTTCGTTCCAGAAAAAAACCTTGGCATCGTAATGTTGGCA
AACAAAAGCTACCCCAACCCGGCTCGCGTCGAGGCGGCCTGGCGCATTCTTGAAAAACTG
CAATAA

# Drug_Target_2_General_Function:
Defense mechanisms and antibiotic degradation

# Drug_Target_2_General_References:
1969344	Tsukamoto K, Tachibana K, Yamazaki N, Ishii Y, Ujiie K, Nishida N, Sawai T: Role of lysine-67 in the active site of class C beta-lactamase from Citrobacter freundii GN346. Eur J Biochem. 1990 Feb 22;188(1):15-22.
2300174	Oefner C, D'Arcy A, Daly JJ, Gubernator K, Charnas RL, Heinze I, Hubschwerlen C, Winkler FK: Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis. Nature. 1990 Jan 18;343(6255):284-8.
3263684	Sawai T, Yamaguchi A, Tsukamoto K: Amino acid sequence, active-site residue, and effect of suicide inhibitors on cephalosporinase of Citrobacter freundii GN346. Rev Infect Dis. 1988 Jul-Aug;10(4):721-5.
3486121	Lindberg F, Normark S: Sequence of the Citrobacter freundii OS60 chromosomal ampC beta-lactamase gene. Eur J Biochem. 1986 May 2;156(3):441-5.
3496243	Yamaguchi A, Adachi H, Sawai T: Identification of the active site of Citrobacter freundii beta-lactamase using dansyl-penicillin. FEBS Lett. 1987 Jun 22;218(1):126-30.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2635

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
41976

# Drug_Target_2_Name:
Beta-lactamase

# Drug_Target_2_Number_of_Residues:
381

# Drug_Target_2_PDB_ID:
1RGY

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00144	Beta-lactamase

# Drug_Target_2_Protein_Sequence:
>Beta-lactamase precursor
MMKKSICCALLLTASFSTFAAAKTEQQIADIVNRTITPLMQEQAIPGMAVAIIYEGKPYY
FTWGKADIANNHPVTQQTLFELGSVSKTFNGVLGGDRIARGEIKLSDPVTKYWPELTGKQ
WRGISLLHLATYTAGGLPLQIPGDVTDKAELLRFYQNWQPQWTPGAKRLYANSSIGLFGA
LAVKSSGMSYEEAMTRRVLQPLKLAHTWITVPQSEQKNYAWGYLEGKPVHVSPGQLDAEA
YGVKSSVIDMARWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNWPLKA
DSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGIVMLA
NKSYPNPARVEAAWRILEKLQ

# Drug_Target_2_Reaction:
a beta-lactam + H2O = a substituted beta-amino acid

# Drug_Target_2_Signals:
1-20

# Drug_Target_2_Specific_Function:
This protein is a serine beta-lactamase with a substrate specificity for cephalosporins

# Drug_Target_2_SwissProt_ID:
P05193

# Drug_Target_2_SwissProt_Name:
AMPC_CITFR

# Drug_Target_2_Synonyms:
Beta-lactamase precursor
Cephalosporinase
EC 3.5.2.6

# Drug_Target_2_Theoretical_pI:
9.39

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00355
